Category Archives: News and Events

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+(TM) for Prostate Cancer

Bria-PROS+ is BriaCell’s next generation personalized off-the-shelf immunotherapy for prostate cancer Immune stimulating components of ...

BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University ...

BriaCell Phase 3 Bria-IMT(TM) Study Enrollment Surpasses 230 Patients

Over 315 patients screened and over 230 patients enrolled in BriaCell’s pivotal Phase 3 Bria-ABC ...

BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

PHILADELPHIA and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Receives FDA Clearance to Initiate Bria-BRES+(TM) Clinical Study in Breast Cancer

FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical ...

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presented Biomarker ...

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) in Preclinical Cancer Models

Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro ...

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, ...

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell to Present Positive Clinical Data for Bria-IMT(TM) and Preclinical Data for Next Generation Bria-OTS+(TM) Personalized Immunotherapy at the 2026 AACR Conference

PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...